https://charts.traderzeitung.de/phases/IE00B91XRN20 string(1412) "{"isin":"IE00B91XRN20","name":"Prothena Corp PLC","stock_id_xnas":7872904,"stock_id_xnys":null,"generated_at":"2026-08-21 13:26:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.705,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.285,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":6.6628},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":9.2,"close_at":"2026-08-20 15:28:00","complete":true,"perf_pct":-0.9155},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.04,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-1.7391},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Prothena Aktie News & Nachrichten

[WKN: A1KAVV | Symbol: PRTA]

Realtimekurs

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

10J

Alles

Artikel aus der Redaktion der Trader-Zeitung

24.02.2025 um 15 Uhr

Prothena

Prothena (PRTA): Birtamimab bietet enorme Möglichkeiten bei der Behandlung der AL-Amyloidose - H.C. Wainwright sieht 207 % Kurspotenzial!

Prothena Corporation plc (PRTA) ist ein irisches biopharmazeutisches Unternehmen. Der Fokus der Forschung...

Prothena Nachrichtenticker öffnen

MT Newswires 05.06.2026 19:55 Uhr

Prothena Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Prothena (PRTA): Birtamimab bietet enorme Möglichkeiten bei der Behandlung der AL-Amyloidose - H.C. Wainwright sieht 207 % Kurspotenzial!

Prothena Corp Public Ltd Insider kaufte Aktien im Wert von $465.295, laut einer aktuellen SEC-Einreichung

Prothena Corp Public Ltd Insider kaufte Aktien im Wert von $471.300, laut einer aktuellen SEC-Einreichung

Prothena Insider kaufte Aktien im Wert von $981.300, laut einer aktuellen SEC-Einreichung